Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Celldex (NASDAQ:CLDX), Sangamo Biosciences (NASDAQ:SGMO) and Endo International (NASDAQ:ENDP).
Celldex (CLDX)
In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Celldex. The company’s shares opened today at $0.48, close to its 52-week low of $0.41.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.6% and a 47.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Celldex has an analyst consensus of Moderate Buy, with a price target consensus of $2.15.
See today’s analyst top recommended stocks >>
Sangamo Biosciences (SGMO)
In a report released yesterday, Ritu Baral from Cowen & Co. initiated coverage with a Buy rating on Sangamo Biosciences. The company’s shares opened today at $14.80.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.0% and a 55.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sangamo Biosciences with a $10 average price target.
Endo International (ENDP)
Canaccord Genuity analyst Dewey Steadman maintained a Hold rating on Endo International yesterday and set a price target of $13. The company’s shares opened today at $16.09, close to its 52-week high of $17.34.
Steadman wrote:
“We are pleased with Endo’s beat and raise quarter as the company continues to pivot itself into a more specialized company with foci on durable brands like Xiaflex, specialty injectables and a specialty generic base business. As such, the strength in the shares seen post earnings likely indicates that investors are pleased with management’s recent actions (as are we). At the same time we continue to view current debt levels, ongoing opioid litigation, and legal liabilities as significant overhangs on the name that could stunt momentum and remain HOLD rated on ENDP shares.”
According to TipRanks.com, Steadman is a 3-star analyst with an average return of 5.0% and a 43.1% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Perrigo Company plc.
Currently, the analyst consensus on Endo International is a Moderate Buy with an average price target of $13.75, which is a -14.5% downside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Hold rating on the stock with a $12 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
